| NMO (n = 18) | RM (n = 15) |
---|---|---|
Female (%) | 15 (83%) | 15 (100%) |
Mean onset age in years (range) | 40.1 (18-64) | 45.7 (17-70) |
Mean duration of follow-up in years (range) | 6.8 (2-16) | 5.1 (1-12) |
Mean number of AM attack (range) | 3.1 (2-9) | 2.7 (2-5) |
Patients with LETM (%) | 17 (94%) | 12 (80%) |
Mean number of ON attacks (range) | 1.9 (1-6) | not applicable |
Mean relapse rate in first 2 years in number of attack per year (range) | 1.5 (0.5-4.0) | 0.8 (0.3-2.0) |
Mean length of MRI T2W hyperintense signal abnormalities in number of vertebral segments (range) | 4.9 (1-16) | 4.2 (1-10) |
Patients with MRI brain lesions compatible with inflammatory demyelination (%) | 10 (56%) | 6 (40%) |
Patients with CSF OCB (%) | 3 (17%) | 3 (20%) |
Patients with other autoimmune disorders or autoantibodies (%) | 9 (50%) | 7 (47%) |
Patients with poor visual outcome (%) | 7 (39%) | not applicable |
Mean EDSS score at latest follow-up (range) | 5.9 (2.0-10) | 5.4 (1.0-10) |
Patients with poor neurological outcome (%) | 12 (67%) | 10 (67%) |
Mortality | 2 (11%) | 2 (13%) |